Olena Popazova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Olena Popazova has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Igor Belenichev
Department of Pharmacology and Medical Formulation with Course of Normal Physiology, Zaporizhzhia State Medical and Pharmaceutical University, 69000 Zaporizhzhia, Ukraine
24 shared publications - Oleksandr Kamyshnyi
Department of Microbiology, Virology and Immunology, I. Horbachevsky Ternopil State Medical University, 46001 Ternopil, Ukraine
15 shared publications - Nina Bukhtiyarova
Department of Clinical Laboratory Diagnostics, Zaporizhzhia State Medical and Pharmaceutical University, 69035 Zaporizhzhia, Ukraine
14 shared publications - Valentyn Oksenych
Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology (NTNU), 7028 Trondheim, Norway
13 shared publications - Victor Ryzhenko
Department of Medical and Pharmaceutical Informatics and Advanced Technologies, Zaporizhzhia State Medical and Pharmaceutical University, 69000 Zaporizhzhia, Ukraine
13 shared publications - Olena Aliyeva
Department of Histology, Cytology and Embryology, Zaporizhzhia State Medical and Pharmaceutical University, 69035 Zaporizhzhia, Ukraine
7 shared publications
Latest Publications
- Open Access
- 25 September 2026
- Published by MDPI AG in Metabolites
- Vol. 16 (10) , 715
Cardioprotective Effects of Coupled SH/NO System Modulators in a Rat Model of Doxorubicin-Induced Heart Failure
Background: The high prevalence of chronic heart failure (CHF) in industrialized countries, alongside its grave consequences—including increased mortality, disability, functional impairment, and reduced quality of life—underscores the urgent need to optimize core medical therapy. In this regard, metabolic cardioprotectants are of particular interest, as their action is aimed at interrupting or mitigating the cascade of adverse metabolic reactions and enhancing the compensatory and adaptive mechanisms of the heart. The aim of this study was to evaluate the effect of sulfur-containing pharmacological agents—namely, N-acetylcysteine (NAC), Heptral, Thiotriazoline, and Angiolin—on selected parameters of the NO and thiol-disulfide systems in the hearts of rats with experimental doxorubicin-induced CHF, followed by an assessment of their cardioprotective efficacy. Methods: CHF was modeled in 70 male Wistar rats weighing 180–190 g by intraperitoneal administration of doxorubicin at a cumulative dose of 15 mg/kg, divided into 6 injections over 14 days. The investigated drugs were administered intragastrically once daily as a suspension in 1% starch mucilage for 30 days following the 14-day doxorubicin protocol: Angiolin ([(S)-2,6-diaminohexanoic acid 3-methyl-1,2,4-triazolyl-5-thioacetate], 100 mg/kg), Thiotriazoline (morpholinium thiazotate, 100 mg/kg), NAC (100 mg/kg), Heptral (S-adenosylmethionine, 100 mg/kg), and Mildronate (250 mg/kg). In the rat myocardium, key components of the NO and thiol-disulfide systems—iNOS, eNOS, nitrotyrosine, stable NO metabolites, glutathione peroxidase-4 (GPX4), glutathione reductase (GR), reduced glutathione (GSH), and oxidized glutathione (GSSG)—were determined using enzyme-linked immunosorbent assay (ELISA), biochemical assays, and real-time PCR. In serum, cardio-specific biomarkers were measured, including the creatine kinase-MB isoenzyme (CK-MB), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and soluble ST2 protein (sST2). Results: It was established that on day 45 following the 14-day doxorubicin administration, alongside a significant elevation in CK-MB, NT-proBNP, and sST2 levels (p < 0.05), there was a concurrent upregulation of iNOS mRNA expression, iNOS protein levels, and nitrotyrosine formation, accompanied by a downregulation of eNOS mRNA expression, eNOS protein levels, and stable NO metabolites (p < 0.05). Furthermore, heart tissue from CHF rats exhibited depletion of the glutathione pool within the thiol-disulfide system, characterized by decreased GPX4, GR, and GSH levels alongside increased GSSG concentrations (p < 0.05). Course administration of the test pharmacological agents to experimental animals post-CHF induction resulted in an improvement in the evaluated parameters of the coupled NO and thiol-disulfide systems, as well as overall cardioprotection. The study analysis demonstrated that Angiolin was statistically superior to Heptral and Mildronate, whereas Thiotriazoline and NAC outperformed Mildronate. Conclusions: These findings confirm the potential cardioprotection provided by modulators of the SH/NO system. Based on these results, further preclinical investigation of Angiolin as a promising cardioprotective agent for CHF is experimentally substantiated.
- 25 September 2026
- Published by MDPI AG in Metabolites
- Vol. 16 (10) , 715
Open AccessCardioprotective Effects of Coupled SH/NO System Modulators in a Rat Model of Doxorubicin-Induced Heart Failure
Background: The high prevalence of chronic heart failure (CHF) in industrialized countries, alongside its grave consequences—including increased mortality, disability, functional impairment, and reduced quality of life—underscores the urgent need to optimize core medical therapy. In this regard, metabolic cardioprotectants are of particular interest, as their action is aimed at interrupting or mitigating the cascade of adverse metabolic reactions and enhancing the compensatory and adaptive mechanisms of the heart. The aim of this study was to evaluate the effect of sulfur-containing pharmacological agents—namely, N-acetylcysteine (NAC), Heptral, Thiotriazoline, and Angiolin—on selected parameters of the NO and thiol-disulfide systems in the hearts of rats with experimental doxorubicin-induced CHF, followed by an assessment of their cardioprotective efficacy. Methods: CHF was modeled in 70 male Wistar rats weighing 180–190 g by intraperitoneal administration of doxorubicin at a cumulative dose of 15 mg/kg, divided into 6 injections over 14 days. The investigated drugs were administered intragastrically once daily as a suspension in 1% starch mucilage for 30 days following the 14-day doxorubicin protocol: Angiolin ([(S)-2,6-diaminohexanoic acid 3-methyl-1,2,4-triazolyl-5-thioacetate], 100 mg/kg), Thiotriazoline (morpholinium thiazotate, 100 mg/kg), NAC (100 mg/kg), Heptral (S-adenosylmethionine, 100 mg/kg), and Mildronate (250 mg/kg). In the rat myocardium, key components of the NO and thiol-disulfide systems—iNOS, eNOS, nitrotyrosine, stable NO metabolites, glutathione peroxidase-4 (GPX4), glutathione reductase (GR), reduced glutathione (GSH), and oxidized glutathione (GSSG)—were determined using enzyme-linked immunosorbent assay (ELISA), biochemical assays, and real-time PCR. In serum, cardio-specific biomarkers were measured, including the creatine kinase-MB isoenzyme (CK-MB), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and soluble ST2 protein (sST2). Results: It was established that on day 45 following the 14-day doxorubicin administration, alongside a significant elevation in CK-MB, NT-proBNP, and sST2 levels (p < 0.05), there was a concurrent upregulation of iNOS mRNA expression, iNOS protein levels, and nitrotyrosine formation, accompanied by a downregulation of eNOS mRNA expression, eNOS protein levels, and stable NO metabolites (p < 0.05). Furthermore, heart tissue from CHF rats exhibited depletion of the glutathione pool within the thiol-disulfide system, characterized by decreased GPX4, GR, and GSH levels alongside increased GSSG concentrations (p < 0.05). Course administration of the test pharmacological agents to experimental animals post-CHF induction resulted in an improvement in the evaluated parameters of the coupled NO and thiol-disulfide systems, as well as overall cardioprotection. The study analysis demonstrated that Angiolin was statistically superior to Heptral and Mildronate, whereas Thiotriazoline and NAC outperformed Mildronate. Conclusions: These findings confirm the potential cardioprotection provided by modulators of the SH/NO system. Based on these results, further preclinical investigation of Angiolin as a promising cardioprotective agent for CHF is experimentally substantiated.
- Open Access
- 1 July 2026
- Published by MDPI AG in Medical Sciences Forum
- Vol. 46 (1) , 6
Shared Endothelial Alterations in Cerebral and Cardiac Vessels in Rat Models of Ischemic Heart Disease and Prenatal Hypoxia
Introduction: Endothelial dysfunction (ED) is a key pathogenetic mechanism underlying cardiovascular and cerebrovascular diseases and is increasingly recognized as a common link between ischemic heart pathology and cerebral vascular impairment. In addition to postnatal risk factors, adverse intrauterine conditions, particularly prenatal hypoxia (PH), may program long-term endothelial alterations. The aim of this study was to investigate the structural and molecular features of ED in the myocardial and cerebral vessels in experimental chronic heart failure (CHF) and PH, as well as to evaluate the endothelioprotective potential of pharmacological agents targeting the nitric oxide system. Methods: This study was conducted on Wistar rats using experimental models of CHF (doxorubicin administration, cumulative dose 15 mg/kg) and PH (sodium nitrite 50 mg/kg administered to pregnant females on gestational days 16–21). The endothelial status of cerebral and myocardial vessels was assessed using immunohistochemistry, ELISA, morphometric analysis, and real-time PCR. Key markers of endothelial function, inflammation, nitric oxide metabolism, oxidative stress, and angiogenesis were evaluated. The endothelioprotective potential of nitric oxide-modulating pharmacological agents was also evaluated. Results: CHF and PH induced pronounced structural and functional endothelial alterations in the microcirculatory and muscular-type vessels of the heart and brain. These changes were characterized by reduced endothelial cell density, suppressed eNOS expression, increased iNOS expression, nitric oxide deficiency, elevated nitrotyrosine levels, and activation of proinflammatory cytokines. VEGF levels were significantly decreased, while apoptotic features of endothelial cells were intensified. Angiolin and Hypertril demonstrated the most pronounced endothelioprotective effects among the tested agents. Conclusions: CHF and PH induce persistent ED in cerebral and myocardial vessels through disruption of the nitric oxide system, oxidative stress, and inflammatory activation. PH may act as an early trigger increasing susceptibility to cardiovascular and cerebrovascular diseases later in life. These findings support the rationale for targeted endothelioprotective therapy in ischemic cardiovascular pathology.
- 1 July 2026
- Published by MDPI AG in Medical Sciences Forum
- Vol. 46 (1) , 6
Open AccessShared Endothelial Alterations in Cerebral and Cardiac Vessels in Rat Models of Ischemic Heart Disease and Prenatal Hypoxia
Introduction: Endothelial dysfunction (ED) is a key pathogenetic mechanism underlying cardiovascular and cerebrovascular diseases and is increasingly recognized as a common link between ischemic heart pathology and cerebral vascular impairment. In addition to postnatal risk factors, adverse intrauterine conditions, particularly prenatal hypoxia (PH), may program long-term endothelial alterations. The aim of this study was to investigate the structural and molecular features of ED in the myocardial and cerebral vessels in experimental chronic heart failure (CHF) and PH, as well as to evaluate the endothelioprotective potential of pharmacological agents targeting the nitric oxide system. Methods: This study was conducted on Wistar rats using experimental models of CHF (doxorubicin administration, cumulative dose 15 mg/kg) and PH (sodium nitrite 50 mg/kg administered to pregnant females on gestational days 16–21). The endothelial status of cerebral and myocardial vessels was assessed using immunohistochemistry, ELISA, morphometric analysis, and real-time PCR. Key markers of endothelial function, inflammation, nitric oxide metabolism, oxidative stress, and angiogenesis were evaluated. The endothelioprotective potential of nitric oxide-modulating pharmacological agents was also evaluated. Results: CHF and PH induced pronounced structural and functional endothelial alterations in the microcirculatory and muscular-type vessels of the heart and brain. These changes were characterized by reduced endothelial cell density, suppressed eNOS expression, increased iNOS expression, nitric oxide deficiency, elevated nitrotyrosine levels, and activation of proinflammatory cytokines. VEGF levels were significantly decreased, while apoptotic features of endothelial cells were intensified. Angiolin and Hypertril demonstrated the most pronounced endothelioprotective effects among the tested agents. Conclusions: CHF and PH induce persistent ED in cerebral and myocardial vessels through disruption of the nitric oxide system, oxidative stress, and inflammatory activation. PH may act as an early trigger increasing susceptibility to cardiovascular and cerebrovascular diseases later in life. These findings support the rationale for targeted endothelioprotective therapy in ischemic cardiovascular pathology.
- Open Access
- 30 April 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (5) , 1018
The Influence of Basic Therapy and New Drugs on NO-Dependent Mechanisms of Cardiac Destruction in Chronic Heart Failure
Chronic heart failure (CHF) remains a leading cause of global mortality, characterized by profound molecular and biochemical disturbances, including nitric oxide (NO) system dysfunction, mitochondrial impairment, and oxidative stress. While standard therapies such as ACE inhibitors, SGLT2 inhibitors, and beta-blockers address clinical symptoms, their capacity to interrupt the underlying biochemical mechanisms of cardiomyopathy is often limited. This review examines the pathophysiological role of impaired NO production and reactive oxygen species (ROS) accumulation in exacerbating myocardial contractile dysfunction and disease progression. Special focus is directed toward the development of next-generation β1-blockers with multifunctional properties, including antioxidant, NO-mimetic, and antiapoptotic effects. Evidence suggests that the novel compound Hypertril (1-(β-phenylethyl)-4-amino-1,2,4-triazolium bromide) exhibits significant cardioprotective potential. Experimental data indicate that Hypertril improves eNOS/iNOS expression and enhances NO bioavailability more effectively than conventional β-blockers, leading to stabilized ECG parameters and restored energy metabolism. These findings underscore the clinical relevance of developing NO-mimetic agents to optimize the pharmacological management of CHF.
- 30 April 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (5) , 1018
Open AccessThe Influence of Basic Therapy and New Drugs on NO-Dependent Mechanisms of Cardiac Destruction in Chronic Heart Failure
Chronic heart failure (CHF) remains a leading cause of global mortality, characterized by profound molecular and biochemical disturbances, including nitric oxide (NO) system dysfunction, mitochondrial impairment, and oxidative stress. While standard therapies such as ACE inhibitors, SGLT2 inhibitors, and beta-blockers address clinical symptoms, their capacity to interrupt the underlying biochemical mechanisms of cardiomyopathy is often limited. This review examines the pathophysiological role of impaired NO production and reactive oxygen species (ROS) accumulation in exacerbating myocardial contractile dysfunction and disease progression. Special focus is directed toward the development of next-generation β1-blockers with multifunctional properties, including antioxidant, NO-mimetic, and antiapoptotic effects. Evidence suggests that the novel compound Hypertril (1-(β-phenylethyl)-4-amino-1,2,4-triazolium bromide) exhibits significant cardioprotective potential. Experimental data indicate that Hypertril improves eNOS/iNOS expression and enhances NO bioavailability more effectively than conventional β-blockers, leading to stabilized ECG parameters and restored energy metabolism. These findings underscore the clinical relevance of developing NO-mimetic agents to optimize the pharmacological management of CHF.
- Open Access
- 16 June 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (6) , 743
Molecular and Biochemical Mechanisms of Cardiomyopathy Development Following Prenatal Hypoxia—Focus on the NO System
Prenatal hypoxia (PH) adversely affects the development of the fetal heart, contributing to persistent cardiovascular impairments in postnatal life. A key component in regulating cardiac physiology is the nitric oxide (NO) system, which influences vascular tone, myocardial contractility, and endothelial integrity during development. Exposure to PH disrupts NO-related signaling pathways, leading to endothelial dysfunction, mitochondrial damage, and an escalation of oxidative stress—all of which exacerbate cardiac injury and trigger cardiomyocyte apoptosis. The excessive generation of reactive nitrogen species drives nitrosative stress, thereby intensifying inflammatory processes and cellular injury. In addition, the interplay between NO and hypoxia-inducible factor (HIF) shapes adaptive responses to PH. NO also modulates the synthesis of heat shock protein 70 (HSP70), a critical factor in cellular defense against stress. This review emphasizes the involvement of NO in cardiovascular injury caused by PH and examines the cardioprotective potential of NO modulators—Angiolin, Thiotriazoline, Mildronate, and L-arginine—as prospective therapeutic agents. These agents reduce oxidative stress, enhance endothelial performance, and alleviate the detrimental effects of PH on the heart, offering potential new strategies to prevent cardiovascular disorders in offspring subjected to prenatal hypoxia.
- 16 June 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (6) , 743
Open AccessMolecular and Biochemical Mechanisms of Cardiomyopathy Development Following Prenatal Hypoxia—Focus on the NO System
Prenatal hypoxia (PH) adversely affects the development of the fetal heart, contributing to persistent cardiovascular impairments in postnatal life. A key component in regulating cardiac physiology is the nitric oxide (NO) system, which influences vascular tone, myocardial contractility, and endothelial integrity during development. Exposure to PH disrupts NO-related signaling pathways, leading to endothelial dysfunction, mitochondrial damage, and an escalation of oxidative stress—all of which exacerbate cardiac injury and trigger cardiomyocyte apoptosis. The excessive generation of reactive nitrogen species drives nitrosative stress, thereby intensifying inflammatory processes and cellular injury. In addition, the interplay between NO and hypoxia-inducible factor (HIF) shapes adaptive responses to PH. NO also modulates the synthesis of heat shock protein 70 (HSP70), a critical factor in cellular defense against stress. This review emphasizes the involvement of NO in cardiovascular injury caused by PH and examines the cardioprotective potential of NO modulators—Angiolin, Thiotriazoline, Mildronate, and L-arginine—as prospective therapeutic agents. These agents reduce oxidative stress, enhance endothelial performance, and alleviate the detrimental effects of PH on the heart, offering potential new strategies to prevent cardiovascular disorders in offspring subjected to prenatal hypoxia.
- Open Access
- 7 April 2025
- Published by MDPI AG in Preprints.org
Molecular and Biochemical Mechanisms of Cardiomyopathy Development Following Prenatal Hypoxia—Focus on the NO System
Prenatal hypoxia (PH) disrupts fetal heart development and induces persistent cardiovascular dysfunction in offspring. The nitric oxide (NO) system is pivotal in regulating myocardial function, influencing vascular tone, contractility, and endothelial integrity during development. PH alters NO signaling, leading to endothelial dysfunction, mitochondrial damage, and oxidative stress, which exacerbate myocardial impairment and increase cardiomyocyte apoptosis. Elevated nitrosative stress, through excessive reactive nitrogen species, further exacerbates these effects, promoting inflammation and cellular injury. The interaction between NO and hypoxia-inducible factor (HIF) also mediates adaptive responses to PH. Additionally, NO modulates the expression of heat shock protein 70 (HSP70), providing cellular protection under stress. This review highlights the role of NO in PH-induced cardiovascular damage and evaluates the therapeutic potential of NO modulators—Angiolin, Tiotriazoline, Mildronate, and L-arginine—as promising agents for cardioprotection. These compounds mitigate oxidative stress, improve endothelial function, and counteract the adverse effects of PH on the heart, suggesting novel therapeutic strategies for preventing cardiovascular dysfunction in offspring exposed to prenatal hypoxia.
- 7 April 2025
- Published by MDPI AG in Preprints.org
Open AccessMolecular and Biochemical Mechanisms of Cardiomyopathy Development Following Prenatal Hypoxia—Focus on the NO System
Prenatal hypoxia (PH) disrupts fetal heart development and induces persistent cardiovascular dysfunction in offspring. The nitric oxide (NO) system is pivotal in regulating myocardial function, influencing vascular tone, contractility, and endothelial integrity during development. PH alters NO signaling, leading to endothelial dysfunction, mitochondrial damage, and oxidative stress, which exacerbate myocardial impairment and increase cardiomyocyte apoptosis. Elevated nitrosative stress, through excessive reactive nitrogen species, further exacerbates these effects, promoting inflammation and cellular injury. The interaction between NO and hypoxia-inducible factor (HIF) also mediates adaptive responses to PH. Additionally, NO modulates the expression of heat shock protein 70 (HSP70), providing cellular protection under stress. This review highlights the role of NO in PH-induced cardiovascular damage and evaluates the therapeutic potential of NO modulators—Angiolin, Tiotriazoline, Mildronate, and L-arginine—as promising agents for cardioprotection. These compounds mitigate oxidative stress, improve endothelial function, and counteract the adverse effects of PH on the heart, suggesting novel therapeutic strategies for preventing cardiovascular dysfunction in offspring exposed to prenatal hypoxia.
- Open Access
- 18 January 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (1) , 108
Targeting Mitochondrial Dysfunction in Cerebral Ischemia: Advances in Pharmacological Interventions
The study of mitochondrial dysfunction has become increasingly pivotal in elucidating the pathophysiology of various cerebral pathologies, particularly neurodegenerative disorders. Mitochondria are essential for cellular energy metabolism, regulation of reactive oxygen species (ROS), calcium homeostasis, and the execution of apoptotic processes. Disruptions in mitochondrial function, driven by factors such as oxidative stress, excitotoxicity, and altered ion balance, lead to neuronal death and contribute to cognitive impairments in several brain diseases. Mitochondrial dysfunction can arise from genetic mutations, ischemic events, hypoxia, and other environmental factors. This article highlights the critical role of mitochondrial dysfunction in the progression of neurodegenerative diseases and discusses the need for targeted therapeutic strategies to attenuate cellular damage, restore mitochondrial function, and enhance neuroprotection.
- 18 January 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (1) , 108
Open AccessTargeting Mitochondrial Dysfunction in Cerebral Ischemia: Advances in Pharmacological Interventions
The study of mitochondrial dysfunction has become increasingly pivotal in elucidating the pathophysiology of various cerebral pathologies, particularly neurodegenerative disorders. Mitochondria are essential for cellular energy metabolism, regulation of reactive oxygen species (ROS), calcium homeostasis, and the execution of apoptotic processes. Disruptions in mitochondrial function, driven by factors such as oxidative stress, excitotoxicity, and altered ion balance, lead to neuronal death and contribute to cognitive impairments in several brain diseases. Mitochondrial dysfunction can arise from genetic mutations, ischemic events, hypoxia, and other environmental factors. This article highlights the critical role of mitochondrial dysfunction in the progression of neurodegenerative diseases and discusses the need for targeted therapeutic strategies to attenuate cellular damage, restore mitochondrial function, and enhance neuroprotection.
- Open Access
- 16 January 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (1) , 106
Possibility of Using NO Modulators for Pharmacocorrection of Endothelial Dysfunction After Prenatal Hypoxia
Prenatal hypoxia (PH) is a key factor in the development of long-term cardiovascular disorders, which are caused by various mechanisms of endothelial dysfunction (ED), including those associated with NO deficiency. This emphasizes the potential of therapeutic agents with NO modulator properties, such as Thiotriazoline, Angiolin, Mildronate, and L-arginine, in the treatment of PH. Methods: Pregnant female rats were given a daily intraperitoneal dose of 50 mg/kg of sodium nitrite starting on the 16th day of pregnancy. A control group of pregnant rats received saline instead. The resulting offspring were divided into the following groups: Group 1—intact rats; Group 2—rat pups subjected to prenatal hypoxia (PH) and treated daily with physiological saline; and Groups 3 to 6—rat pups exposed to prenatal hypoxia and treated daily from the 1st to the 30th day after birth. Levels of sEPCR, Tie2 tyrosine kinase, VEGF-B, SOD1/Cu-Zn SOD, GPX4, and GPX1 in the heart’s cytosolic homogenate were assessed using ELISA. The expression of VEGF and VEGF-B mRNA was analyzed via real-time polymerase chain reaction, and the nuclear area of myocardial microvessel endothelial cells was evaluated morphometrically. Results: We have shown that only two representatives of this group—Angiolin and Thiotriazoline—are able to exert full effect on the indices of endothelial dysfunction after PH to decrease sEPCR, increase Tie-2, VEGF-B and VEGF-B mRNA, Cu/ZnSOD, and GPX in myocardial cytosol, and increase the area of endotheliocyte nuclei in 1- and 2-month-old rats in comparison with the control. Conclusions: Our results experimentally substantiate the necessity of early postnatal cardio- and endothelioprotection using NO modulators, taking into account the role of NO-dependent mechanisms in the pathogenesis of cardiovascular system disorders in neonates after PH.
- 16 January 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (1) , 106
Open AccessPossibility of Using NO Modulators for Pharmacocorrection of Endothelial Dysfunction After Prenatal Hypoxia
Prenatal hypoxia (PH) is a key factor in the development of long-term cardiovascular disorders, which are caused by various mechanisms of endothelial dysfunction (ED), including those associated with NO deficiency. This emphasizes the potential of therapeutic agents with NO modulator properties, such as Thiotriazoline, Angiolin, Mildronate, and L-arginine, in the treatment of PH. Methods: Pregnant female rats were given a daily intraperitoneal dose of 50 mg/kg of sodium nitrite starting on the 16th day of pregnancy. A control group of pregnant rats received saline instead. The resulting offspring were divided into the following groups: Group 1—intact rats; Group 2—rat pups subjected to prenatal hypoxia (PH) and treated daily with physiological saline; and Groups 3 to 6—rat pups exposed to prenatal hypoxia and treated daily from the 1st to the 30th day after birth. Levels of sEPCR, Tie2 tyrosine kinase, VEGF-B, SOD1/Cu-Zn SOD, GPX4, and GPX1 in the heart’s cytosolic homogenate were assessed using ELISA. The expression of VEGF and VEGF-B mRNA was analyzed via real-time polymerase chain reaction, and the nuclear area of myocardial microvessel endothelial cells was evaluated morphometrically. Results: We have shown that only two representatives of this group—Angiolin and Thiotriazoline—are able to exert full effect on the indices of endothelial dysfunction after PH to decrease sEPCR, increase Tie-2, VEGF-B and VEGF-B mRNA, Cu/ZnSOD, and GPX in myocardial cytosol, and increase the area of endotheliocyte nuclei in 1- and 2-month-old rats in comparison with the control. Conclusions: Our results experimentally substantiate the necessity of early postnatal cardio- and endothelioprotection using NO modulators, taking into account the role of NO-dependent mechanisms in the pathogenesis of cardiovascular system disorders in neonates after PH.
- 1 January 2025
- Published by Publishing House Helvetica (Publications) in Fitoterapia
- No. 3,p. 53-61
Therapeutic efficacy of hirudo verbana leech extract in a thermal wound model
- 1 January 2025
- Published by Publishing House Helvetica (Publications) in Fitoterapia
- No. 3,p. 53-61
Therapeutic efficacy of hirudo verbana leech extract in a thermal wound model
- Open Access
- 20 December 2024
- Published by MDPI AG in Preprints.org
Formation of Mitochondrial Dysfunction of Nerve Cells in Cerebral Ischemia and Possibilities of Pharmacological Correction
The study of mitochondrial dysfunction has become increasingly pivotal in elucidating the pathophysiology of various cerebral pathologies, particularly neurodegenerative disorders. Mitochondria are essential for cellular energy metabolism, regulation of reactive oxygen species (ROS), calcium homeostasis, and the execution of apoptotic processes. Disruptions in mitochondrial function, driven by factors such as oxidative stress, excitotoxicity, and altered ion balance, lead to neuronal death and contribute to cognitive impairments in several brain diseases. Mitochondrial dysfunction can arise from genetic mutations, ischemic events, hypoxia, and other environmental factors. This article highlights the critical role of mitochondrial dysfunction in the progression of neurodegenerative diseases and discusses the need for targeted therapeutic strategies to attenuate cellular damage, restore mitochondrial function, and enhance neuroprotection.
- 20 December 2024
- Published by MDPI AG in Preprints.org
Open AccessFormation of Mitochondrial Dysfunction of Nerve Cells in Cerebral Ischemia and Possibilities of Pharmacological Correction
The study of mitochondrial dysfunction has become increasingly pivotal in elucidating the pathophysiology of various cerebral pathologies, particularly neurodegenerative disorders. Mitochondria are essential for cellular energy metabolism, regulation of reactive oxygen species (ROS), calcium homeostasis, and the execution of apoptotic processes. Disruptions in mitochondrial function, driven by factors such as oxidative stress, excitotoxicity, and altered ion balance, lead to neuronal death and contribute to cognitive impairments in several brain diseases. Mitochondrial dysfunction can arise from genetic mutations, ischemic events, hypoxia, and other environmental factors. This article highlights the critical role of mitochondrial dysfunction in the progression of neurodegenerative diseases and discusses the need for targeted therapeutic strategies to attenuate cellular damage, restore mitochondrial function, and enhance neuroprotection.
- Open Access
- 4 November 2024
- Published by MDPI AG in Preprints.org
Success of Nitric Oxide System Modulators in Pharmacocorrection of Some Indicators of Endothelial Dysfunction After Intrauterine Hypoxia
Prenatal hypoxia plays a crucial role in programming long-term cardiovascular dysfunction through mechanisms like endothelial dysfunction and nitric oxide system impairment, highlighting the potential of therapeutic agents, such as thiotriazoline, angiolin, mildronate, and L-arginine, for mitigating these adverse effects. Methods. Levels of sEPCR, Tie2 tyrosine kinase, VEGF-B, SOD1/Cu-Zn SOD, GPX4, and GPX1 were measured in the heart's cytosolic homogenate using ELISA. Results. Modeling prenatal hypoxia (PH) resulted in significant alterations in the concentrations of proteins linked to endothelial function and oxidative stress in the heart cytosol of experimental animals, including an increase in sEPCR and reductions in Tie-2, VEGF-B, Cu/ZnSOD, GPX4, and GPX1 levels. Postnatal administration of nitric oxide modulators (L-arginine, thiotriazoline, angiolin, and mildronate) demonstrated differential efficacy in normalizing these proteins. Notably, angiolin produced the most substantial therapeutic effect, restoring Tie2, VEGF-B, and antioxidant enzyme levels to near-normal levels. Our results highlight the efficacy of Angiolin and Thiotriazoline in restoring endothelial function and antioxidant enzyme levels in the car-diovascular system following prenatal hypoxia, supporting their potential as early postnatal in-terventions to prevent long-term cardiovascular dysfunction.
- 4 November 2024
- Published by MDPI AG in Preprints.org
Open AccessSuccess of Nitric Oxide System Modulators in Pharmacocorrection of Some Indicators of Endothelial Dysfunction After Intrauterine Hypoxia
Prenatal hypoxia plays a crucial role in programming long-term cardiovascular dysfunction through mechanisms like endothelial dysfunction and nitric oxide system impairment, highlighting the potential of therapeutic agents, such as thiotriazoline, angiolin, mildronate, and L-arginine, for mitigating these adverse effects. Methods. Levels of sEPCR, Tie2 tyrosine kinase, VEGF-B, SOD1/Cu-Zn SOD, GPX4, and GPX1 were measured in the heart's cytosolic homogenate using ELISA. Results. Modeling prenatal hypoxia (PH) resulted in significant alterations in the concentrations of proteins linked to endothelial function and oxidative stress in the heart cytosol of experimental animals, including an increase in sEPCR and reductions in Tie-2, VEGF-B, Cu/ZnSOD, GPX4, and GPX1 levels. Postnatal administration of nitric oxide modulators (L-arginine, thiotriazoline, angiolin, and mildronate) demonstrated differential efficacy in normalizing these proteins. Notably, angiolin produced the most substantial therapeutic effect, restoring Tie2, VEGF-B, and antioxidant enzyme levels to near-normal levels. Our results highlight the efficacy of Angiolin and Thiotriazoline in restoring endothelial function and antioxidant enzyme levels in the car-diovascular system following prenatal hypoxia, supporting their potential as early postnatal in-terventions to prevent long-term cardiovascular dysfunction.